| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| |
|
|
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection |
|
|
|
|
| |
Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G. Clin Gastroenterol Hepatol. 2012 Nov 14. pii: S1542-3565(12)01386-9. doi: 10.1016/j.cgh.2012.10.045. [Epub ahead of print] |
|
| |
|
|
| |
Source
Vertex Pharmaceuticals, Inc, Cambridge, Massachusetts.
Abstract
For patients treated with telaprevir, peginterferon, and ribavirin, futility rules have been developed to prevent needless drug exposure and minimize development of drug-resistant variants for patients who have little or no chance of achieving a sustained virologic response. We performed retrospective analyses of data from phase 3 trials and validated the current futility rule. All therapy should be stopped for treatment-naive and treatment-experienced patients if hepatitis C virus RNA levels are greater than 1000 IU/mL at weeks 4 or 12, or if hepatitis C virus RNA is detectable at week 24.
|
|
|
|
| |
| |
|
